Current therapies for gastro-oesophageal reflux in the setting of chronic lung disease: state of the art review

• Published in: ERJ open research 2020-10, Vol.6 (4), p.190
• Main Authors: McDonnell, Melissa J, Hunt, Eoin B, Ward, Chris, Pearson, Jeffrey P, O'Toole, Daniel, Laffey, John G, Murphy, Desmond M, Rutherford, Robert M
• Format: Article
• Language: English
• Subjects: Reviews
• ISSN: 2312-0541; 2312-0541
• DOI: 10.1183/23120541.00190-2019

The inter-relationship between chronic respiratory disease and reflux disease in the airway reflux paradigm is extremely complex and remains poorly characterised. Reflux disease is reported to cause or contribute to the severity of a number of respiratory tract diseases including laryngeal disorders, sinusitis, chronic cough, asthma, COPD, idiopathic pulmonary fibrosis, cystic fibrosis, bronchiectasis and bronchiolitis obliterans post lung transplant. It is now appreciated that reflux disease is not simply caused by liquid acid reflux but rather by a variety of chemical refluxates originating from the stomach and duodenum due to a number of different mechanisms. Reflux disease can be challenging to diagnose, particularly proving its role in the causation of direct respiratory epithelial damage. Significant advances in oesophageal assessment and gastric biomarkers have emerged in recent years as our understanding increases. There are a number of treatments available for reflux disease, both medical and surgical, but there is a paucity of large randomised trials to evaluate their efficacy in the setting of chronic respiratory disease. Everyday clinical practice, however, informs us that treatment failure in reflux disease is common. This clinical review summarises associations between reflux disease in the setting of chronic respiratory diseases and examines available evidence regarding potential therapeutic strategies.